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Abstract
Introduction: Angiogenesis represents a potential therapeutic target in breast cancer. However, responses to
targeted antiangiogenic therapies have been reported to vary among patients. This suggests that the tumor
vasculature may be heterogeneous and that an appropriate choice of treatment would require an understanding
of these differences.
Methods: To investigate whether and how the breast tumor vasculature varies between individuals, we isolated
tumor-associated and matched normal vasculature from 17 breast carcinomas by laser-capture microdissection, and
generated gene-expression profiles. Because microvessel density has previously been associated with disease
course, tumors with low (n = 9) or high (n = 8) microvessel density were selected for analysis to maximize
heterogeneity for this feature.
Results: We identified differences between tumor and normal vasculature, and we describe two subtypes present
within tumor vasculature. These subtypes exhibit distinct gene-expression signatures that reflect features including
hallmarks of vessel maturity. Potential therapeutic targets (MET, ITGAV, and PDGFRb) are differentially expressed
between subtypes. Taking these subtypes into account has allowed us to derive a vascular signature associated
with disease outcome.
Conclusions: Our results further support a role for tumor microvasculature in determining disease progression.
Overall, this study provides a deeper molecular understanding of the heterogeneity existing within the breast
tumor vasculature and opens new avenues toward the improved design and targeting of antiangiogenic therapies.
Introduction
The growth of tumors beyond a certain size requires the
recruitment of an adequate blood supply, which is sup-
plied by abnormal angiogenesis. This involves the trigger-
ing of an “angiogenic switch” [1], whereby the tumor
microenvironment enters a proangiogenic mode in
response to hypoxia. This process is accompanied by
increased levels of multiple proangiogenic factors, includ-
ing vascular endothelial growth factor A (VEGFA) and
platelet-derived growth factor B (PDGFB), as well as
decreases in antiangiogenic factors such as endostatin.
This leads to an increase in the number of proliferating
endothelial cells, along with enhanced endothelial cell
recruitment and migration toward the tumor bed [2].
Because endothelial cells are considered to be genetically
stable [2], modulation of angiogenic processes is consid-
ered to be a promising area for cancer therapy. However,
clinical trials of antiangiogenic therapies in breast cancer
have reported mixed results [3-5]. Heterogeneity among
tumor vasculatures may partially explain this lack of con-
sistency [3]. The most common measure of vascular het-
erogeneity is microvessel density (MVD), which has weak
prognostic value in breast cancer [6]. MVD is significantly
associated with histologic type, but does not appear to be
linked to other features, including nodal status, tumor
grade, estrogen receptor (ER) status, molecular subtype, or
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the presence of vascular invasion [7,8]. However, other
characteristics of the tumor vasculature, such as vascular
proliferation and levels of circulating endothelial progeni-
tor cells, also have clinical significance in cancer [9,10].
Therefore, a more complete understanding of vascular
heterogeneity is required.
Gene-expression profiling studies have provided a
greater understanding of breast tumor heterogeneity
[11,12] and have highlighted the role of the stroma in
influencing disease outcome [13-16]. However, previous
studies of tumor vasculature have mostly been limited to
small numbers of samples and have focused on direct
comparisons between tumor-associated and normal vascu-
lature [17-23]. Although these studies have identified
alterations characteristic of the tumor vasculature perse,
they have not addressed the question of vascular heteroge-
neity or investigated whether distinct intertumoral vascular
subtypes exist. Here, we use laser-capture microdissection
(LCM) to isolate tumor-associated and matched normal
microvascular compartments separately from 17 human
breast cancer samples. After gene-expression profiling, we
identified and validated gene-expression signatures that
define two distinct subtypes of tumor vasculature, an
understanding of which would represent an important
step toward the improved design and targeting of thera-
peutic modalities.
Materials and methods
Tissue samples from 21 patients undergoing surgery for
primary invasive ductal carcinoma (IDC) with no prior
neoadjuvant therapy, and from one patient undergoing
reduction mammoplasty, were subjected to LCM (see
Additional File 1, Table S1A, B). From this cohort, we
obtained 17 samples of tumor-associated vasculature; in 15
cases, we also obtained normal vasculature. After determi-
nation of MVD (see Additional File 2, Figure S1A),
PECAM1-positive cells (microvasculature) were collected
by using LCM from within tumor beds (n = 17), as well as
from morphologically normal tissue adjacent to breast
tumors (n = 14) and from one reduction mammoplasty
(sample V) (see Additional File 2, Figure S1B). Only
PECAM1-positive cells present within capillaries and small
vascular structures were collected, avoiding isolated
PECAM1-positive cells and vessels with large lumens.
Total RNA was extracted, amplified, labeled, and hybri-
dized on Agilent 44K Whole Genome arrays (Agilent
Technologies, Santa Clara, CA). The endothelial and
epithelial cell content of isolated samples was assessed
by quantitative real-time PCR (qRT-PCR) (see Additional
File 2, Figure S1C).
Description of samples
Clinical information was collected on a prospective basis
(median follow-up, 5.6 years; see Additional File 1,
Table S1B). Occurrence of distant recurrence was deter-
mined by examination of medical records. Matched nor-
mal epithelial samples were obtained as previously
described [24]. This study was approved by the McGill
University Health Centre Research Ethics Board (Proto-
cols SDR-99-780 and SDR-00-966). All patients provided
written, informed consent.
Laser-capture microdissection, RNA isolation, and
microarray hybridization
Immunohistochemistry directed against PECAM1 for
MVD quantitation was carried out as per the antibody
manufacturer’s instructions. Quantitation of PECAM1
staining density was performed by averaging the stained
pixel intensity of three fields captured at 10 × magnifi-
cation by using imageJ [25]. Details of the anti-PECAM1
immunohistochemistry protocol used for guided LCM
are presented in Supplementary Information (see Addi-
tional File 3, Supplementary Materials and Methods).
LCM, RNA isolation and sample preparation, as well as
microarray hybridization, were carried out as previously
described [13]. Microarray results have been submitted
to the Gene Expression Omnibus (GSE15363).
Differential expression, class discovery, and class
prediction
All analyses were performed using R/Bioconductor ver-
sion 2.6 [26]. Microarray data were extracted as described
in Supplementary Information (see Additional File 3,
Supplementary Materials and Methods). Initially, the set
of most-variable probes (n = 1,168) was defined as those
with an interquartile range above 2. Class discovery was
performed by hierarchical clustering based on this set,
using Ward’s minimum-variance method with a correla-
tion distance metric. The significance of the resulting
clusters was calculated by using the pvclust package with
10,000 bootstrap iterations. Heatmaps were generated by
scaling each row (gene) into Z-scores, subtracting the
mean and dividing by its standard deviation. Differential
expression between sample sets was determined by using
Linear Models for Microarray Analysis (LIMMA) [27].
For genes represented by multiple probes, only the probe
with the largest interquartile range was used. Unless sta-
ted otherwise, a gene was considered differentially
expressed if the FDR-adjusted P value was ≤0.05 [28].
Predictors of recurrence were generated as follows:
gene expression for subtype B member profiles was
adjusted by removing the average differences between
subtype B and subtype A tumor vascular expression for
each gene. Then, the six most significantly differentially
expressed genes between recurrent and nonrecurrent
tumor vasculature were identified by using a Wilcoxon
rank-sum test. These genes were used to train a linear
discriminant analysis classifier and tested for accuracy
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through leave-one-out cross-validation (LOOCV). All
steps (including the adjustment of tumor vascular sub-
types) were done under cross-validation. Gene sets of
size two to 100 were tested for prediction, and six-gene
predictors were found to exhibit the highest accuracy
under LOOCV.
Quantitative real-time PCR and immunohistochemistry
Validation for selected genes and cognate proteins was
performed by qRT-PCR and IHC, respectively, on subsets
of samples. Full details and probe sequences are presented
in Supplementary Information (see Additional File 3, Sup-
plementary Materials and Methods).
Results and discussion
Because our goal was to investigate the heterogeneity of
the tumor microvasculature in invasive ductal carcinomas,
samples with high and low MVD were chosen to maxi-
mize the spectrum of heterogeneity present within the
sample cohort. Within this set, we identified tumor sam-
ples with high (n = 8) or low (n = 9) MVD, as determined
by immunohistochemistry directed against the endothelial
marker PECAM1 (see Additional File 1; Table S1B; Addi-
tional File 2, Figure S1A).
Isolation of vasculature-enriched samples and gene-
expression profiling
A significant enrichment of PECAM1 was observed in
microdissected vasculature when compared with the
epithelial cell marker cytokeratin 8 (KRT8); conversely,
the latter marker was enriched in matched microdis-
sected epithelial RNA samples (see Additional File 2,
Figure S1C). These results indicate that the vascular
samples are highly enriched in endothelial cell content.
Tumor and normal vasculatures possess distinct
expression profiles
To investigate the differences among the expression pro-
files generated, we performed hierarchical clustering by
using the 1,168 most variable genes (interquartile range
>2) over the entire dataset. The normal and tumor vascu-
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Figure 1 Gene expression identifies two distinct subtypes of breast tumor vasculature. (A) Hierarchical clustering separates normal (blue)
and tumor vascular samples and segregates the tumors into two clusters (orange, magenta). Clusters in the tree are labeled with the
percentage of times they were observed in 10,000 bootstrap iterations. Clinical characteristics for tumor samples: red, high/positive; white, low/
negative. Tumor size is represented as a gradient from white (smallest tumor) to red (largest tumor). Clinical variables are not presented for
samples from normal vasculature (left side). (B) Schematic depiction of pathways and processes differentially expressed between normal
vasculature, tumor vasculature as a whole, and the two tumor vascular subtypes. Edges are labeled with the number of differentially expressed
genes for each comparison. (C) Heatmap of genes differentially expressed between any two of the normal, A and B subtypes (FDR < 0.0001).
Also presented are details of three functionally related groups: 1, normal vascular genes; 2, angiogenesis-inhibitor genes; and 3, classic tumor
vascular genes. Heatmap colors represent Z-scores for each gene (red, high expression; green, low expression). (D) Ordering of samples by
expression of pericyte markers demonstrates that these are more highly expressed in subtype B members.
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Additional File 2, Figure S2A). Further comparison of the
tumor and normal vasculature samples identified 494 dif-
ferentially expressed genes (FDR < 0.05, LIMMA; see
Additional File 4, Sheet 1).
A significant overlap exists between the gene sets
discriminating between tumor and normal vasculature
identified by previous studies [17-23] and here (P < 0.05
for each, Fisher Exact test; Figure S3A). This overlap is
significant even for the studies performed on different
tumor types [19-23] or by using other isolation techni-
ques [18-20,23]. Common processes include extracellular
matrix remodeling and cytokine signaling [29] (see Addi-
tional File 1, Table S2). Several genes previously reported
to be elevated in tumor vasculature [29] are also elevated
in our tumor vascular cohort, including osteonectin
(SPARC), collagens 1A1, 3A1, 4A2, and 18A1 (COL1A1,
COL3A1, COL4A2 and COL18A1), and Thy cell-surface
antigen (THY1) (see Additional File 4, Sheet 1). This is
consistent with the observation that tumor vasculature is
constantly reorganizing [30,31] and confirms that our
normal and tumor vasculature are comparable to those
isolated in previous studies.
The tumor vasculature also exhibits differential expres-
sion of genes related to oxidative phosphorylation/stress
and MAPK signaling (Figure 1B; see Additional File 1,
Table S2; Additional File 4, Sheet 1). It is known that
reoxygenation of vasculature, consistent with the variable
flow of blood in tumor vessels, leads to the creation of
reactive oxygen species [32].
Tumor vascular expression profiles segregate into two
distinct subtypes reflecting different biological processes
Interestingly, the hierarchical clustering revealed that the
tumor samples form two distinct clusters, here termed A
and B (Figure 1A; see Additional File 1, Figure S2A); this
separation was also reflected in the first component
when the set of tumor vascular samples were subjected
to principal-component analysis (see Additional File 1,
Figure S2B). Analysis of differential expression between
these two clusters identifies 1,659 genes (FDR < 0.05,
LIMMA; see Additional File 4, Sheet 2). This is more
than 3 times larger than the number of genes differen-
tially expressed between normal and tumor samples,
emphasizing the significance of the clusters and indicat-
ing that homogeneity within each cluster is higher than
that within the tumor vasculature as a whole. Thus,
separating tumor samples by cluster may prove more
informative than grouping them together.
The tumor vascular clusters are independent of major
clinical variables, including ER and HER2 status, grade, and
lymph node involvement (P ≥ 0.6; see Additional File 1,
Table S1A) but are enriched for larger and smaller tumors
as well as high and low MVD (P <0.05, t test). Interestingly,
no statistically significant differential gene expression was
found between high- and low-MVD samples (FDR < 0.05,
LIMMA). This demonstrates that although MVD status is
associated with the tumor vascular clusters identified here,
additional properties of the samples are primarily responsi-
ble for the molecular profiles and observed clustering.
To identify biological functions specifically associated
with each of the two subtypes of tumor vasculature, we
identified the most highly differentially expressed genes
(FDR < 0.0001, LIMMA, Figure 1C; FDR < 0.05, LIMMA;
see Additional File 4, Sheet 2) and pathways (FDR < 0.05;
Figure 1B; see Additional File 1, Table S2) between nor-
mal vasculature and each of the tumor vascular subtypes
A and B.
Genes within Group 1 exhibit the highest expression
in normal samples and the lowest expression in tumor-
associated vasculature subtype A members (Figure 1C).
Interestingly, these include AOC3 and FOXO1, both
associated with vascular shear stress [33,34]. Reduced
shear stress suggests a decreased flow rate, consistent
with the hypothesis that tumor vessels, and in particular
those belonging to subtype A, lack appropriate perfusion
[35]. Many genes and processes related to metabolism
and biosynthesis are also overrepresented in subtype A
(see Additional File 1, Table S2; Additional File 4, Sheet
2), suggesting active proliferation. Consistent with this,
Group 2, consisting of genes whose expression is ele-
vated in subtype A (Figure 1C), includes cathepsin B
(CTSB), associated with active vascular remodeling
[35,36].
Genes within Group 3 are more highly expressed in
subtype B, and are enriched for elements involved in
interactions with the extracellular matrix, collagen pro-
duction, focal adhesion, hypoxia, glycolysis, immune
response, and protein export, suggesting that this group
may represent a more stable vasculature (Figure 1C;
Additional File 1, Table S2). These include genes
involved in antiangiogenic processes, such as thrombos-
pondin 2 (THBS2) and the collagens COL18A1 and
COL4A2, which can be cleaved to form endostatin and
canstatin, respectively [37]. Antiangiogenic signaling
from these and other genes (see Additional File 1, Fig-
ure S3B) may contribute to the decreased overall MVD
seen in these samples. Interestingly, NOTCH3 is also
elevated in subtype B (see Additional File 4, Sheet 2);
Notch signaling is implicated in vascular development
and maturation [38,39].
Tumor vasculature is often considered immature with
respect to normal vasculature [30], the known functions
of many of the individual genes identified here suggest
that the two tumor vascular clusters may represent dif-
ferences in degree of vascular maturity. This hypothesis
was investigated by using several approaches. Pericytes
line mature capillary vessels and would be co-isolated
with PECAM1-positive endothelial cells during LCM,
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whereas the association of pericytes with immature ves-
sels is relatively loose, and this cell type would therefore
be co-isolated at a lower frequency in such vessels [31].
Therefore, we explored whether clusters A and B dif-
fered with respect to their content of pericyte-specific
signals, specifically the pericyte markers ACTA2,
PDGFRb, and RGS5 [40], as well as LAMB1, a surrogate
of laminin-8 (a4b1g1) implicated in vessel maturation
[41] (Figure 1D). Interestingly, these markers are ele-
vated in cluster B (P <0.05 for each; t test), and their
expression pattern successfully recapitulates the clusters
(Figure 1D). Differential expression of PDGFRb was
confirmed by qRT-PCR on amplified RNA prepared
from tumor vascular samples (see Additional File 2, Fig-
ure S3C), whereas immunohistochemistry (IHC)-based
validation was also performed for ACTA2 and LAMB1
(Figure 2A, B; see Additional File 2, Figure S4A). Serial
staining directed against PECAM1 showed that most
ACTA2 and LAMB1 expression is observed in proximity
to the PECAM1-expressing vasculature (see Additional
File 2, Figure S4B, C), while pixel counts over whole sec-
tions (normalized for PECAM1 staining, as assessed on a
neighboring section) showed a significantly increased
expression of ACTA2 and LAMB1 in tumors belonging
to cluster B (P <0.05 for each, Wilcoxon test; Figure 2C;
Additional File 1, Table S1A). Therefore, the differential
gene expression observed between clusters is recapitu-
lated at the protein level for these markers. In addition,
assessment of LAMB1 mRNA content in selected sam-
ples by qRT-PCR significantly correlated with the micro-
array-derived values; this also held true for several other
selected genes (see Additional File 2, Figure S5). Support-
ing this observation, a negative correlation between
MVD and pericyte coverage has also been identified in
endometrial cancer [9].
To assess whether the subtype B-specific gene-expression
profile is driven by pericyte-specific genes, the sample















































Figure 2 Immunohistochemistry directed against selected subtype markers confirms their differential expression between subtypes.
(A) Anti-ACTA2 immunohistochemistry. Individual sample labels are indicated in italic font in the upper left corner of each image. Each image is
of a representative 1 × 1-mm area; inset depicts whole section; scale bar in inset, 1 mm. (B) Bar plot of pixel counts for IHC staining of ACTA2
and LAMB1, relative to PECAM1 staining.
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subtype-specific gene expression were compared (see Addi-
tional File 2, Figure S6). First, we confirmed that ordering
of all samples by relative expression of known pericyte
markers recapitulated the separation of subtype A and B
members (Additional File 2, Figure S6A, B); this ordering
was not correlated with expression of endothelial marker
genes (Additional File 2, Figure S6C). Subtype B members
were then ordered by relative expression of known pericyte
markers (Additional File 2, Figure S6D). Then, retaining
this ordering, the relative expression of the top 200 genes
differentially expressed between the A and B subtypes
(ranked by P value) was examined (see Additional File 2,
Figure S6E). Importantly, no correlation was seen at the
sample level between relative pericyte-marker content and
relative expression levels of subtype-specific genes within
the set of subtype B members, supporting that processes
other than those linked to pericyte-marker content distin-
guish these two subtypes.
Pathway analysis highlights an increased expression of
genes related to glycolysis and oxidative phosphorylation
in subtype B (Figure 1B). This is intriguing, as elevation
of either glycolysis or oxidative phosphorylation often
leads to downregulation of the other [42]. Coupled with
an increased expression of ribosomal genes, the increase
in oxidative phosphorylation could be evidence of
increased metabolism in subtype B vasculature. Interest-
ingly, the different tumor vascular subtypes also vary at
the level of NK and T-cell marker expression, suggesting
that vascular subtypes can affect the tumor microenvir-
onment. Additionally, CXCL12/SDF-1, considered to play
a role in pericyte recruitment [43], is decreased in sub-
type A tumor vasculature relative to subtype B, consis-
tent with the presence of increased levels of pericyte
markers in subtype B, whereas angiopoietin-2 (ANGPT2),
thought to promote blood-vessel destabilization by acting
as an ANGPT1 antagonist [44], is elevated in subtype B
tumor vasculature.
Together, these results strongly support the hypothesis
that the vascular clusters observed here reflect differences
in vessel maturity, and indicate that related processes,
including anti- and proangiogenic regulators and matrix
remodeling, also contribute to the segregation of the vascu-
lar subtypes. We suggest that cluster B, associated with low
MVD, may represent samples with a more mature tumor
vasculature with respect to members of cluster A. Other
potential factors driving cluster segregation may include
unidirectional shear stress (USS), expected to be highest in
vessels of subtype B. USS elicits an antiinflammatory
response [45] and has been shown to induce miR-21
expression in endothelial cells, leading to decreased apop-
tosis and activation of the nitric oxide pathway, implicated
in Notch signaling [46]. All of these are consistent with our
proposed subtypes (Figure 1B). Interestingly, genes pre-
viously identified as being commonly overexpressed in
tumor endothelium and therefore proposed as specific
markers for endothelial cell targeting, including SPARC
and COL4A1 [47], are elevated in subtype B but not sub-
type A tumor vasculature, accentuating the importance of
gaining a better understanding of the heterogeneity present
in this compartment.
Most previous signatures of tumor vascular cells identify
only tumor vascular subtype B
Previous studies (see Additional File 2, Figure S3A) have
generated signatures that segregate tumor versus normal
vascular samples, but have not identified distinct subtypes
within the tumor vasculature. To test whether these signa-
tures can differentiate between our tumor vascular sub-
types, we examined the clustering induced by previously
reported tumor vascular signatures [17,18,21-23] in our
dataset. All previously published tumor vascular gene sets
investigated could segregate members of subtype B from
normal samples in our data (Figure 3; Additional File 2,
Figure S3D-G); however, only the gene set described by
Bhati et al. [17] generated from breast tumors using LCM,
successfully segregates the subtype A and normal samples
(Figure 3A). The inability of most existing datasets to gen-
erate signatures capable of distinguishing between tumor
vascular subtypes may be partially explained by differences
in the isolation technique used. Unlike LCM, immuno-
magnetic bead-based approaches using dispersed cells fail
to isolate cells adjacent to the vessels that can provide
additional information about the vascular microenviron-
ment. Additionally, differences in the tissue of origin may
contribute to these observations (see Additional File 2,
Figure S3A), suggesting that subtype A may be enriched
in breast tumors, and supporting the concept of tissue-
specific antiangiogenic approaches.
The ability of the tumor vascular signature from Bhati
et al. [17] to partially recapitulate our tumor vascular sub-
types (Figure 3A) suggests that their samples contained
features of both subtypes, and indicates that this vascular
heterogeneity is likely to be common in breast cancer.
Bhati et al. [17] used laser-capture microdissection to iso-
late factor VIII-expressing vascular cells from human
breast cancers and normal breast tissue; however, they
failed to identify subtypes within the tumor sample set.
This may partly be due to the restricted sample size used
in their study (n = 5), whereas the increased size of our
patient cohort (n = 17), in combination with our selection
based on MVD, likely enabled us to capture a broader
range of interpatient variation in tumor vasculature. The
small number of samples investigated in most previous
studies (n = 1 to 5) [17-20,22,23] also raises the possibility
that only members of one subtype were present in their
study cohorts. Hence our identification and initial charac-
terization of distinct breast cancer vasculature subtypes is
a novel finding that emphasizes the concept that breast
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cancer heterogeneity extends to the different subcompo-
nents of the tumor microenvironment.
Gene-expression differences induced by subtype
membership mask differential gene expression associated
with disease outcome
To determine whether differences in tumor vasculature
gene expression were correlated with other aspects of
tumor biology and disease course, we performed differen-
tial expression analysis between the five recurrent and 12
nonrecurrent tumor samples in our dataset. This identified
a total of 128 genes (P < 0.01, no adjustment: see Addi-
tional File 1, Table S3), including TLR2 (involved in innate
immunity) [48] and GAB1 (a scaffold protein linked to
VEGF signaling and endothelial migration) [49]. Subtype
membership is not correlated with recurrence in our rela-
tively small dataset. This agrees with previous reports that
differences in vessel maturity are associated with lymph
node status but not other clinical variables in breast cancer
[50]. However, we speculated that the differences in gene
expression induced by subtype membership might be suf-
ficiently large to mask differential gene expression asso-
ciated with disease outcome. Similar conclusions have
been drawn regarding gene expression-based predictors of
breast cancer outcome based on whole-tumor data, which
have generally been found to be more reliable when lim-
ited to specific tumor subtypes [51,52]. Generation of sub-
type-specific predictors was not possible, given the small
size of each group and the limited number of recurrences
in each (see Additional File 1, Table S1A,B). Therefore, we
investigated this hypothesis by removing the gene-expres-
sion changes that could be ascribed to subtype member-
ship. This was achieved by calculating the difference in
average expression between the members of the two sub-
types for each probe, and subtracting this value from the
relevant probe data for all members of one subtype. After
this adjustment, we could successfully build a six-gene
predictor that identified recurrent patient samples with
94% accuracy under cross-validation in our dataset (P =
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Figure 3 Tumor context and tissue of origin affects vascular expression in tumor samples. (A) The tumor vascular signature from Bhati et
al. [17] separates tumor from normal vasculature in our samples, and also segregates most members of the A and B subtypes. (B) The tumor
vascular signature from Parker et al. [18] identifies subtype B tumor vasculature, but fails to segregate subtype A tumor vasculature from normal
samples.
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correction, no successful predictor could be constructed.
The fact that the combination of these genes can predict
recurrence under cross-validation within our dataset con-
firms their differential expression, despite their individual
lack of significance after FDR adjustment.
This indicates that vascular markers of recurrence can
be subtype-specific and that the subtypes contain differ-
ent markers linked to recurrence. Additionally, the
observation that successful construction of a predictor
cannot be achieved without taking the inter-subtype dif-
ferences into account suggests that these differences are
sufficiently large to mask signals associated with other
clinical variables, and supports that tumor vascular sub-
types must be taken into account in future analyses of
this compartment.
Our earlier work established that breast tumor stroma
as a whole contains sufficient information to predict
recurrence independently [13]. This study highlights
that features of patient-specific vasculatures can reflect
differences in the tumor microenvironment predictive of
recurrence. As such, the tumor vasculature, including its
subtypes, should be considered when studying the deter-
minants of recurrence. This adds another dimension to
previous reports that different characteristics of vascula-
ture are associated with tumor stage and metastasis
[6,9,10,53], and indicates that the effects of tumor vascu-
lature on disease progression are complex. Further
research will be necessary to identify successfully all
relevant factors contributed by the vascular environment
in tumor progression.
Drug targets are differentially expressed between
subtypes
The existence of vascular subtypes has important impli-
cations for the choice of antiangiogenic treatment strate-
gies. A substantial proportion of patients in such clinical
trials fail to show clinical benefits [3,4]; short-term treat-
ment with one antiangiogenic drug led to an increased
incidence of metastasis [54]. Importantly, observed dif-
ferences between our subtypes (for example, pericyte
coverage) may reflect mechanisms of resistance to anti-
angiogenic therapy [4]. Pericyte coverage can reduce
tumor vessel vulnerability to VEGF inhibition, and in
such cases, targeting treatments against both pericytes
and endothelial cells may lead to improved efficacy [55].
The targets of several antiangiogenic drugs [56,57] are
also differentially expressed between subtypes (Figure 4B).
Both PDGFRb and MET (a receptor tyrosine kinase, whose
natural ligand HGF is a potent angiogenic factor [58]), are
elevated in subtype B; antagonists to av integrin (ITGAV)
[59], also elevated in subtype B, have been shown to block
neovascularization. Vessel maturity has been linked to
resistance to antiangiogenic therapy in melanoma [60],


























































































































−3 −1 1 2 3Row Z−Scores −2 0
Figure 4 Tumor vascular subtypes suggest potential
prognostic and predictive biomarkers. (A) Heatmap depicting
expression of the six genes composing the prognostic predictor
(above, in red), as well as the top 50 (Table S3) genes differentially
expressed with recurrence in tumor vascular samples. A higher
prediction score represents a higher likelihood of recurrence. The
prediction score was calculated under cross-validation. Clinical
variables are presented as in Figure 1A. (B) List of antiangiogenic
drug targets [56] whose expression differs between the tumor
vascular subtypes.
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tumor types. The differential expression of drug targets
indicates that subtype-specific approaches to targeting
tumor angiogenesis may lead to improved response rates
by permitting prestratification of patient populations.
Modifications of the tumor vasculature, as suggested by a
recent study identifying vessel normalization through abla-
tion of the endothelial oxygen sensor PHD2 as a potential
means to improve the delivery and efficacy of chemothera-
peutic agents [61], may also have subtype-specific effects.
The identification of biomarkers for prediction of response
to antiangiogenic therapy is a current critical clinical need
[62], and the vascular-subtype gene-expression profiles
presented here provide new perspectives for the validation
of such markers.
Conclusions
Overall, our data illustrate the heterogeneity of the
breast tumor vasculature, define two tumor vascular
subtypes that are associated with, but not defined by,
microvessel density, and represent a first step toward
establishing the landscape of vascular subtypes in breast
cancer. Our previous work has shown that heterogeneity
within the stromal compartment of breast tumors is
linked to disease outcome [13]. We now suggest that
breast tumor vasculature heterogeneity also plays a role
in determining disease course, and that further study
thereof may be critical for improved patient stratifica-
tion before selection of specific targeted therapeutic
regimens.
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